Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 3/20 | 0.37 |
| ▸ | ACE | P12821 | 3/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | CPA1 | P15085 | 1/20 | 0.36 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3810013 | 1.00 | CTRB1 (0.37) | CTRB1ACEMMECPA1ACE2 | |
| SCHEMBL9665720 | 1.00 | CTRB1 (0.37) | CTRB1ACEMMECPA1ACE2 | |
| SCHEMBL3916112 | 1.00 | CTRB1 (0.37) | CTRB1ACEMMECPA1ACE2 | |
| SCHEMBL17293240 | 1.00 | CTRB1 (0.37) | CTRB1ACEMMECPA1ACE2 | |
| SCHEMBL749822 | 1.00 | CTRB1 (0.37) | CTRB1ACEMMECPA1ACE2 | |
| SCHEMBL749821 | 1.00 | CTRB1 (0.37) | CTRB1ACEMMECPA1ACE2 | |
| SCHEMBL29511173 | 1.00 | CTRB1 (0.37) | CTRB1ACEMMECPA1ACE2 | |
| Water SCHEMBL29655463 | 0.99 | CTRB1 (0.36) | CTRB1ACEMMECPA1ACE2 | |
| SCHEMBL4587799 | 0.99 | CTRB1 (0.36) | CTRB1ACEMMECPA1ACE2 | |
| SCHEMBL2813159 | 0.99 | CTRB1 (0.36) | CTRB1ACEMMECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021186-A1 | Fatty Acid-D-Amino Acid Peptides Conjugates as Anaplerotic Compounds for Use in Treating Propionic Acidemia, Methylmalonic Acidurias, and Energy Metabolic Disorders | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2026-01-22 | — | — | US | claimed |
| EP-4565325-A2 | FATTY ACID-D-AMINO ACID PEPTIDES CONJUGATES AS ANAPLEROTIC COMPOUNDS FOR USE IN TREATING PROPIONIC ACIDEMIA, METHYLMALONIC ACIDURIAS, AND ENERGY METABOLIC DISORDERS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-06-11 | — | — | EP | claimed |
| CN-119855613-A | Fatty acid-D-amino acid peptide conjugates as anaplerotic compounds for the treatment of hyperuricemia, methylmalonic urine disorder and energy metabolism disorders | 匹兹堡大学高等教育联邦体系 | 2025-04-18 | — | — | CN | claimed |
| WO-2024030367-A2 | FATTY ACID-D-AMINO ACID PEPTIDES CONJUGATES AS ANAPLEROTIC COMPOUNDS FOR USE IN TREATING PROPIONIC ACIDEMIA, METHYLMALONIC ACIDURIAS, AND ENERGY METABOLIC DISORDERS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-02-08 | — | — | WO | claimed |
| US-20260021186-A1 | Fatty Acid-D-Amino Acid Peptides Conjugates as Anaplerotic Compounds for Use in Treating Propionic Acidemia, Methylmalonic Acidurias, and Energy Metabolic Disorders | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4565325-A2 | FATTY ACID-D-AMINO ACID PEPTIDES CONJUGATES AS ANAPLEROTIC COMPOUNDS FOR USE IN TREATING PROPIONIC ACIDEMIA, METHYLMALONIC ACIDURIAS, AND ENERGY METABOLIC DISORDERS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-06-11 | — | — | EP | disclosed |
| CN-119855613-A | Fatty acid-D-amino acid peptide conjugates as anaplerotic compounds for the treatment of hyperuricemia, methylmalonic urine disorder and energy metabolism disorders | 匹兹堡大学高等教育联邦体系 | 2025-04-18 | — | — | CN | disclosed |
| EP-4412655-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDER | Vincerx Pharma GmbH (DE) | 2024-08-14 | — | — | EP | disclosed |
| WO-2024030367-A2 | FATTY ACID-D-AMINO ACID PEPTIDES CONJUGATES AS ANAPLEROTIC COMPOUNDS FOR USE IN TREATING PROPIONIC ACIDEMIA, METHYLMALONIC ACIDURIAS, AND ENERGY METABOLIC DISORDERS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-02-08 | — | — | WO | disclosed |
| WO-2023057812-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDER | VINCERX PHARMA GMBH (DE) | 2023-04-13 | — | — | WO | disclosed |
| EP-2035444-A2 | DIPEPTIDE COMPOUNDS CONTAINING D-HISTIDINE | Flamma S.P.A. (IT) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008001175-A2 | DIPEPTIDE COMPOUNDS CONTAINING D-HISTIDINE | FLAMMA S.P.A. (IT) | 2008-01-03 | — | — | WO | disclosed |
| EP-0304954-A2 | Cyclic dipeptide enantiomers | ICI AUSTRALIA LIMITED (AU) | 1989-03-01 | — | — | EP | disclosed |
| EP-0135691-A2 | Cyanohydrination catalyst | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021186-A1 | Fatty Acid-D-Amino Acid Peptides Conjugates as Anaplerotic Compounds for Use in Treating Propionic Acidemia, Methylmalonic Acidurias, and Energy Metabolic Disorders | HADHB, HADHA, HADH | CTRB1 2009/4885ACE 3221/4885MME 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.